Serabelisib Set To Join PI3K? Fray As Kaken Makes Japan Vascular Filing
US-originated asset has had a complex development history but takes a key step towards possible commercialization for the high-need indication of vascular malformations.
Scrip - July 22, 2026

Ability Neurotech Moves Implantable, Batteryless BCI Into First-In-Human Trial
Ability Neurotech is moving into first-in-human trials with its implantable brain-computer interface. The trial involves capturing neural data from five patients undergoing brain tumor surgery.
Medtech Insight - July 21, 2026

Danaher Posts Strong Q2 Results Driven By Life Sciences And Masimo Acquisition
Danaher’s 2Q 2026 results beat Wall Street expectations and allowed the company to raise its full-year EPS guidance, buoyed by strong life sciences growth and the Masimo acquisition. However, shares dropped on a narrower core revenue growth outlook driven by bioprocessing shipment delays.
Medtech Insight - July 21, 2026

Kandu’s At-Home Brain-Computer Interface Offers a ‘Can-Do’ Approach to Stroke Rehabilitation
Kandu CEO Leo Petrossian explains how IpsiHand — an EEG headset and robotic brace that translates thought into movement — aims to reach the millions of chronic stroke survivors that conventional rehabilitation has left without options.
Medtech Insight - July 21, 2026

DePuy Synthes Buys Expandable-Cage Maker Expanding Innovations Ahead Of J&J Spinoff
J&J's DePuy Synthes has acquired expandable-cage maker Expanding Innovations for undisclosed terms, a tuck-in aimed at the fastest-growing slice of the spine market — and one more move to sharpen the orthopedics unit ahead of a planned spin-off or a reported $20bn-plus sale.
Medtech Insight - July 21, 2026

FDA Tightens Stance On Terumo’s RelayPro: Return The Devices, Don’t Use Them
The FDA has told clinicians to return the recalled RelayPro thoracic stent-grafts to the maker rather than keep using them cautiously — a tightening from earlier notices.
Medtech Insight - July 21, 2026

CorTec’s BCI Shows Early Promise In Stroke Rehab With 8 to 12 Point FMA-UE Gains
CorTec’s implantable BCI system has shown early safety and functional gains in three stroke patients, with Fugl-Meyer (FMA-UE) upper extremity improving by 8-12 points. Rivals Neurolutions, Mobia Medical and Enspire leverage EEG, VNS and DBS technologies respectively also use FMA-UE as benchmark.
Medtech Insight - July 21, 2026

Brands Should “Reinterpret,” Not Imitate, K-Beauty For Local Markets – NielsenIQ
NielsenIQ says beauty brands can successfully leverage the global K-Beauty boom by adapting the innovation, ingredient and marketing strategies behind Korean beauty rather than simply copying products.
HBW Insight - July 22, 2026

Henlius Advances Darzalex And Opdivo Biosimilar Trials
Henlius has dosed the first patients across four biosimilar programs this summer, advancing daratumumab, nivolumab, cetuximab, and ipilimumab candidates in the US and China.
Generics Bulletin - July 21, 2026

Inspection Findings Highlight Hurdles Facing Alvotech’s Launch Plans
An FDA inspection has found continuing quality-system deficiencies at Alvotech’s Reykjavik plant, where manufacturing issues have already delayed several US biosimilar applications.
Generics Bulletin - July 21, 2026

Canadian Generics Face Tougher Path Around Dosing Regimen Patents
Canada’s Supreme Court has upheld Janssen’s Invega Sustenna dosing patent, blocking Pharmascience’s generic and setting a new test focusing on whether claims constrain physicians’ clinical judgment.
Generics Bulletin - July 21, 2026

Dr Reddy’s Bottleneck Stalls Aspen’s Canadian Semaglutide Ambitions
Aspen has won Canadian approval for generic injectable semaglutide, but API supply problems at Dr Reddy’s have delayed commercialization and could weaken its early-mover advantage.
Generics Bulletin - July 21, 2026

AAIC: Blood-Based Alzheimer’s Biomarkers Gain Ground
The Alzheimer’s Association International Conference (AAIC) showed that p-tau217 blood tests are rapidly becoming the "gold standard" for diagnosis – and possibly even prognosis.
In Vivo - July 21, 2026

Podcast: How ElevateBio Is Betting On Every Gene Editing Modality At Once
ElevateBio's CSO Amy Pooler on why no single gene editing modality will dominate, and how AI-designed enzymes and smarter delivery could finally unlock large gene therapies.
In Vivo - July 21, 2026

The Biggest Launches In Pharma History Are Increasingly Forecasts, Not Records
Evaluate data on the biggest drug launches ever shows actual sales topping the table at year three – led by COVID-19 vaccines – before forecasts take over at years five and 10, almost entirely incretin assets. Counted as one franchise, Lilly's tirzepatide approaches $72bn by year 10.
In Vivo - July 21, 2026